BamSEC and AlphaSense Join Forces
Learn More

Genocea Biosciences Inc

Formerly NASDAQ: GNCA
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.30
from 10-K/A ~1 page September 12, 2016 Dear Jess
12/34/56
EX-10.28
from 10-K 37 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark [* * *]. Collaboration & Option Agreement
12/34/56
EX-10.1
from 10-Q 6 pages Genocea Biosciences, Inc. 2014 Equity Incentive Plan Performance-Based Restricted Stock Unit Award Agreement
12/34/56
EX-10.7
from 10-K 35 pages Article 1 Summary of Basic Sublease Provisions
12/34/56
EX-10.1
from 8-K 88 pages Material contract
12/34/56
EX-10.1
from 8-K 10 pages Genocea Biosciences, Inc. Amended and Restated 2014 Equity Incentive Plan
12/34/56
EX-10.3
from 10-Q 3 pages Genocea Biosciences, Inc. 2014 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.2
from 10-Q 12 pages September 17, 2018 Dear Tom: This Letter Agreement (“Agreement”) Sets Forth the Terms and Conditions of Your Offer of Employment With Genocea Biosciences, Inc. (The “Company”). if Accepted, the Terms Hereof Shall Be Effective and Your Employment Shall Commence on October 1, 2018 (The “Effective Date”)
12/34/56
EX-10.1
from 10-Q 12 pages November 6, 2018 Dear Girish: This Letter Agreement ("Agreement") Sets Forth the Terms and Conditions of Your Offer of Employment With Genocea Biosciences, Inc. (The "Company"). if Accepted, the Terms Hereof Shall Be Effective, and Your Employment Shall Commence on December 6, 2018 (The "Effective Date")
12/34/56
EX-10.23
from 10-K 10 pages Second Amendment of Lease
12/34/56
EX-10.2
from 10-K 32 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Genocea Biosciences, Inc. if Publicly Disclosed. Amended and Restated License Agreement
12/34/56
EX-10.1
from 10-Q 10 pages July 22, 2019 as We Have Discussed, This Letter Separation and Transition Agreement (This “Agreement”) Confirms the Terms of the Remainder of Your Employment With Genocea Biosciences, Inc. (The “Company”) and Your Separation From the Company, as Follows: 1.transition Period and Separation Date
12/34/56
EX-10.1
from 10-Q 85 pages Material contract
12/34/56
EX-10.4
from 10-Q >50 pages Agreement
12/34/56
EX-10.2
from 8-K ~10 pages Genocea Biosciences, Inc. 2014 Employee Stock Purchase Plan, as Amended
12/34/56
EX-10.1
from 8-K 17 pages Genocea Biosciences, Inc. Amended and Restated 2014 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 1 page Amendment to Equity Rights Letter Agreement
12/34/56
EX-10.33
from 10-K 2 pages Genocea Biosciences, Inc. Sixth Amendment to Consulting Agreement
12/34/56
EX-10.32
from 10-K ~20 pages This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [* * *] and Has Been Filed Separately With the Securities and Exchange Commission. License and Supply Agreement by and Between Genocea Biosciences, Inc. and Oncovir, Inc
12/34/56
EX-10.1
from 8-K 3 pages Genocea Biosciences, Inc. Sixth Amendment to Consulting Agreement
12/34/56